The report covers emerging Dry Eye Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dry Eye Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dry Eye Disease: An Overview
Dry eye disease (DED), also known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS), is a common condition when the eyes do not produce enough tears or the tears evaporate too quickly. As tears are essential to lubricate and nourish the eye, the condition leads to eyes drying out and becoming red, swollen, and irritated. Causes for DED include decreased tear production, excessive tear evaporation, and abnormality in the production of mucus or lipids of the tear layer.
It is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. It can affect one or both eyes, and it can lead to inflammation.
The main symptom of dry eye is a dry and gritty feeling in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain and redness of the eyes, and photophobia in some cases. Sometimes, it is also associated with a stringy discharge and blurred, changing vision. Besides, the symptoms are found to worsen in dry weather, with low humidity and higher temperatures. Having dry eyes for a while can lead to tiny abrasions on the surface of the eyes. In advanced cases, the epithelium undergoes pathologic changes, namely squamous metaplasia and loss of goblet cells.
Dry Eye Disease Market Key Facts
According to the Association of Optometrists, dry eye is a very common condition in the UK, affecting one in four people in the UK.
According to Siffel et. al (2020), the prevalence and incidence of DED increased with age and were higher in women in Germany.
According to Stapleton et al. (2017), study the global prevalence estimates of DED were reported to be 5–50% with estimates in Europe (specifically, France and UK) ranging from 10% to 22%
According to American Optometric Association (2017), the prevalence of DED among 18 to 34-year-olds was 2.7% compared to 18.6% among adults aged 75 and older. One-half of all diagnosed-DED participants self-reported mild DED severity; 42% and 8% reported moderate or severe DED, respectively.
As per DelveInsight, the Dry Eye Disease Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Dry Eye Disease patients in the 7MM and the expected entry of premium price assets in the market.
Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication to provide better relief for the symptoms and hence improve the QoL of patients with DED. Some of the key players in the market include Novaliq, Palatin Technologies, mc2 therapeutics, and many others. Of the emerging therapies, MC2-03 (mc2 therapeutics), PL9643 (Palatin Technologies), and many other compelling treatments are expected to change the market scenario of Dry Eye Disease in the upcoming years.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dry Eye Disease pipeline therapies. It also thoroughly assesses the Dry Eye Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Dry Eye Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Dry Eye Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Dry Eye Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dry Eye Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Dry Eye Disease Epidemiology, Segmented as –
Total Prevalent Cases of Dry Eye Disease [2019–2032]
Total Diagnosed Cases of Dry Eye Disease [2019–2032]
Type-Specific Diagnosed Cases of Dry Eye Disease [2019–2032]
Severity-specific Prevalent Cases of Dry Eye Disease [2019–2032]
Age-specific Prevalent Cases of Dry Eye Disease [2019–2032]
Gender-specific Prevalence of Dry Eye Disease [2019–2032]
Dry Eye Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dry Eye Disease market or expected to be launched during the study period. The analysis covers the Dry Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Dry Eye Disease drugs based on their sale and market share.
The report also covers the Dry Eye Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dry Eye Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Dry Eye Disease Market Will Evolve and Grow by 2032 @
Dry Eye Disease Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Dry Eye Disease. Currently, RegeneRx Biopharmaceuticals is leading the therapeutics market with its Dry Eye Disease drug candidates in the most advanced stage of clinical development.
“On June 9, 2023, Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved Vevye (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease. Vevye (development name CyclASol) is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after four weeks of treatment, according to the company.”
Dry Eye Disease Companies Actively Working in the Therapeutics Market Include
Oyster Point Pharma
And Many Others
Emerging and Marketed Dry Eye Disease Therapies Covered in the Report Include:
Timbetasin: RegeneRx Biopharmaceuticals
Visu XL/Xailin Hydrate/Xailin Gel: Visufarma
Genteal/Systane/Tears Naturale: Alcon/Novartis
IKERVIS (Cyclosporine): Santen
OC-01: Oyster Pharma
PL9643: Palatin Technologies
Reproxalap: Aldeyra Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dry Eye Disease Competitive Intelligence Analysis
4. Dry Eye Disease Market Overview at a Glance
5. Dry Eye Disease Background and Overview
6. Dry Eye Disease Patient Journey
7. Dry Eye Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Dry Eye Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry Eye Disease Unmet Needs
10. Key Endpoints of Dry Eye Disease Treatment
11. Dry Eye Disease Marketed Therapies
12. Dry Eye Disease Emerging Drugs and Latest Therapeutic Advances
13. Dry Eye Disease Seven Major Market Analysis
14. Attribute Analysis
15. Dry Eye Disease Market Outlook (In US, EU5, and Japan)
16. Dry Eye Disease Companies Active in the Market
17. Dry Eye Disease Access and Reimbursement Overview
18. KOL Views on the Dry Eye Disease Market
19. Dry Eye Disease Market Drivers
20. Dry Eye Disease Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Seborrhoeic Dermatitis market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States